A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.

A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Abstract Text:

Kathleen M Darcy,Chunqiao Tian,Eddie Reed,

To determine whether platinum-DNA adducts and/or mRNA expression of the excision nuclease excision repair cross-complementation group 1 (ERCC1) from peripheral blood leukocytes (PBL) were associated with clinical outcome in women with epithelial ovarian cancer (EOC), participants that had previously untreated, optimally resected, stage III EOC were randomized to paclitaxel plus cisplatin or carboplatin. DNA and RNA were extracted from PBLs collected 20 to 28 h post-drug infusion. DNA adducts were measured by atomic absorption spectroscopy. ERCC1 expression was evaluated by reverse transcription-PCR. There were 170 cases fully evaluable for DNA adducts and ERCC1 mRNA expression. Adduct levels ranged from 0.43 to 131 fmol platinum/microg DNA in 140 samples; and adducts were not detectable in 30 samples. ERCC1 mRNA was detectable in 132 samples and undetectable in 38. ERCC1 mRNA expression in PBLs was not associated with any clinical end point measured. The presence of detectable versus undetectable adducts was associated with longer median progression-free survival (20.4 versus 15.6 months; P = 0.084) and overall survival (60.3 versus 36.3 months; P = 0.029), respectively. Unadjusted Cox regression modeling indicated a trend toward a reduced risk of disease progression [hazard ratio (HR), 0.686; 95% confidence interval (95% CI), 0.447-1.054; P = 0.086] and a statistically significant reduction in the risk of death (HR, 0.607; 95% CI, 0.385-0.958; P = 0.032) for women with detectable versus undetectable adducts. After adjusting for clinicopathologic variables, detectable adducts were not an independent predictor of progression-free survival or overall survival. The presence of platinum-DNA adducts, but not ERCC1 mRNA expression, in PBLs was associated with better survival, but was not an independent predictor of clinical outcome in optimal advanced EOC.

A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Publishing Authors By Initials

KM Darcy,C Tian,E Reed,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Cancer research

VOLUME: 67

Page Numbers: 4474-81

Journal Abbreviation:

ISSN: 0008-5472

DAY: 1

MONTH: May

YEAR: 2007

A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2984705

A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: genetics

Chemical & Substance for Abstract: A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Information

Substance Name: Endonucleases

Registry Number: EC 3.1.-

Grant and Affiliation Information for A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.

AFFILIATION: Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York, USA.

Country: United States

AGENCY: United States NCI

GRANT: CA 37517

ACRONYM: CA

MEDLINETA: Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy Related Publications

• 14th International HLA and Immunogenetics Workshop: report on understanding antibodies in transplantation.
• A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
• A locus on mouse Chromosome 9 (Adip5) affects the relative weight of the gonadal but not retroperitoneal adipose depot.
• A phagocytosis mutant of Entamoeba histolytica is less virulent due to deficient proteinase expression and release.
• An infrared nuNH scale for weakly basic anions. Implications for single-molecule acidity and superacidity.
• An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity.
• Analysis of the Cob(II)alamin-5'-deoxy-3',4'-anhydroadenosyl radical triplet spin system in the active site of diol dehydrase.
• Biochemical and functional comparisons of Mcl-1 and Bcl-2 proteins: evidence for a novel mechanism of regulating Bcl-2 family protein function.
• Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex.
• Cathepsin Cs are key for the intracellular survival of the protozoan parasite, Toxoplasma gondii.
• Daxx represses expression of a subset of antiapoptotic genes regulated by nuclear factor-kappaB.
• Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland.
• Do sitting-atop metalloporphyrin complexes exist? Observation of N-H- - -pi bonding in arene solvates of a diprotonated porphyrin dication.
• Effects of question format and collection mode on the accuracy of retrospective surveys of health risk behavior: a comparison with daily sexual activity diaries.
• Fertility of ewes following artificial insemination with semen frozen in pellets or straws, a preliminary report.
• Free radical mechanisms in enzymology.
• Frequency and amplitude discrimination along the kinestheticcutaneous continuum in the presence of masking stimuli.
• HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesis.
• IR spectrum of the H(5)O(2)(+) cation in the context of proton disolvates L-H(+)-L.
• Mammalian dap3 is an essential gene required for mitochondrial homeostasis in vivo and contributing to the extrinsic pathway for apoptosis.
• Mice lacking bi-1 gene show accelerated liver regeneration.
• Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma.
• Pediatric respiratory and systemic effects of chronic air pollution exposure: nose, lung, heart, and brain pathology.
• Physician patterns of metabolic screening for patients taking atypical antipsychotics: a retrospective database study.
• Probing nitrogen-sensitive steps in the free-radical-mediated deamination of amino alcohols by ethanolamine ammonia-lyase.
• Reasons for unprotected intercourse: analysis of the PRAMS survey.
• Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation.
• Scope of practice for public health professionals and volunteers.
• The empirical relationship between community social capital and the demand for cigarettes.
• Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor (TRAF)-mediated inflammatory responses.